Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer antibody-based therapies.

The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham. French ...

L’Oreal OR0.54%increase; green up pointing triangle will sell part of its stake in Sanofi SAN 0.43%increase; green up pointing triangle back to the French pharmaceutical company for 3 billion ...

Share Buyback Program: EUR5 billion planned for 2025. Sanofi SA (NASDAQ:SNY) achieved double-digit sales growth for the third consecutive quarter, driven by new product launches and strong ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden child could be emerging in the form of Beyfortus. During its first ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

On Friday, Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded Sanofi (EPA:SASY) (NASDAQ:SNY) stock from Sell to Hold and increased the price target to €100.00 from €85.00. The adjustment ...